ObsEva(OTC) OBSV

Market CapN/A

Since IPO (2017)-100%

5 Year-100%

1 Year+0%

1 Month+0%

N/A

ObsEva last closing stock price
Metric	Price	Date
Last close	USD 0.00	2026-08-28

ObsEva stock price return by period
Period	Price return	Price at period start	Period start date
1 week	+0%	USD 0.00	2026-08-21
1 month	+0%	USD 0.00	2026-07-28
3 month	+0%	USD 0.00	2026-05-29
Year to date	+0%	USD 0.00	2025-12-31
1 year	+0%	USD 0.00	2025-08-28
3 year	-99.86%	USD 0.07	2023-08-29
5 year	-100%	USD 2.86	2021-08-27
Since inception	-100%	USD 11.65	2017-01-26

ObsEva Financials at a Glance

Market Cap

N/A

Revenue (TTM)

$19.64M

Net Income (TTM)

-$29.88M

EPS (TTM)

N/A

P/E Ratio

N/A

Dividend

N/A

Beta (Volatility)

N/A

Dividend

N/A

Beta (Volatility)

N/A

Price

N/A

Volume

N/A

Open

N/A

Price

N/A

Volume

N/A

Open

N/A

Previous Close

N/A

Daily Range

N/A

52-Week Range

N/A

Estimated Earnings Date

Aug 15, 2023

Dividend

N/A

Beta (Volatility)

N/A

Price

N/A

Volume

N/A

Open

N/A

Previous Close

N/A

Daily Range

N/A

52-Week Range

N/A

Estimated Earnings Date

Aug 15, 2023

OBSV News

No articles available.

Motley Fool Moneyball Superscore

Our CEO Is Handing Members His Secret Weapon

It's called Motley Fool Moneyball, our new proprietary AI tool

We spent over half a million dollars in R&D to build a tool that makes stock research faster, sharper, and smarter. Our analysts use it every day, and now, you can too.

Get Access Now

About ObsEva

ObsEva S.A. is a biopharmaceutical firm focused on developing innovative treatments for women's reproductive health and pregnancy. The company is advancing several key products through clinical trials, aiming to address significant unmet medical needs in this sector.

Products and Services

Linzagolix: An oral GnRH receptor antagonist in Phase III trials for endometriosis and uterine fibroids
Ebopiprant: A selective oral PGF2a receptor antagonist in Phase II trials for preterm labor
Nolasiban: An oral oxytocin receptor antagonist in Phase I development for IVF outcomes

Growth Outlook

Strong pipeline with multiple products in advanced clinical stages
Potential market expansion as women's health awareness increases
Strategic partnerships may enhance development and commercialization efforts

Financial Highlights

Recent quarterly revenue of $19.6 million, a significant increase from previous quarters
Cash and cash equivalents of $8.4 million as of Q4 2022, supporting ongoing operations
Operating income of $5.2 million in Q4 2022, indicating positive operational momentum

ObsEva S.A. operates in a critical and growing sector, with a focus on women's health issues that are often overlooked. The company's innovative approach to treatment development positions it well for future growth. The recent financial performance reflects a positive trajectory, with increasing revenue and a solid cash position to support ongoing research and development. As the healthcare landscape evolves, ObsEva's commitment to addressing women's reproductive health needs may present significant opportunities for investors.

AI Generated • Aug 26, 2026

Industry

Biotechnology

Sector

Health Care

Employees

CEO

Brian O'Callaghan, MBA

Website

www.obseva.com

Headquarters

Geneva, 1228, CH

OBSV Financials

Key Financial Metrics (TTM)

Gross Margin

100.00%

Operating Margin

-79.83%

Net Income Margin

-152.16%

Return on Equity

-146.39%

Return on Capital

-136.20%

Return on Assets

-180.60%

Earnings Yield

N/A

Dividend Yield

0.00%

Payout Ratio

0.00%

Stock Overview

Market Cap

N/A

Shares Outstanding

N/A

Volume

N/A

Avg. Volume

N/A

Financials (TTM)

Gross Profit

$19.64M

Operating Income

-$34.58M

EBITDA

$13.66M

Operating Cash Flow

-$23.15M

Capital Expenditure

$0.00

Free Cash Flow

-$23.15M

Cash & ST Invst.

$8.42M

Total Debt

$3.03M

ObsEva Performance Analysis

ObsEva annual revenue and year-over-year revenue growth by fiscal year
Fiscal year	Period end	Revenue	YoY growth
2021	2021-12-31	USD 22,200,000	N/A
2022	2022-12-31	USD 19,637,000	-11.5%

ObsEva sequential (quarter-over-quarter) revenue growth by fiscal quarter
Fiscal quarter	Period end	QoQ growth
Q1	2022-03-31	N/A
Q2	2022-06-30	N/A
Q3	2022-09-30	N/A
Q4	2022-12-31	N/A

ObsEva annual diluted earnings per share and year-over-year EPS growth by fiscal year
Fiscal year	Period end	Diluted EPS	YoY growth
2021	2021-12-31	USD -0.70	N/A
2022	2022-12-31	USD -0.32	-53.9%

ObsEva sequential (quarter-over-quarter) diluted earnings per share growth by fiscal quarter
Fiscal quarter	Period end	QoQ growth
Q1	2022-03-31	46.2%
Q2	2022-06-30	-178.6%
Q3	2022-09-30	66.7%
Q4	2022-12-31	323.1%

Revenue Growth Rate

Annual and quarterly growth comparison

Earnings Per Share Growth Rate

Annual and quarterly EPS growth comparison

Quarterly Performance

Name

Q4 2022YOY CHG

Revenue

$19.64M

N/A

Gross Profit

$19.64M

N/A

Gross Margin

100.00%

N/A

Market Cap

N/A

Market Cap/Employee

N/A

Employees

N/A

Net Income

$26.78M

+233.6%

EBITDA

$31.72M

+186.4%

Quarterly Fundamentals

Name

Q4 2022YOY CHG

Total Cash

$8.42M

-84.6%

Total Debt

$3.03M

-88.6%

Accounts Receivable

$252.00K

-92.9%

Inventory

$0.00

N/A

Long Term Debt

$0.00

-100.0%

Short Term Debt

$3.03M

+341.3%

Return on Assets

-1.81%

N/A

Return on Invested Capital

-1.68%

N/A

Free Cash Flow

$7.94M

+162.3%

Operating Cash Flow

$7.92M

+162.1%

Other Investments to Explore

People Also Watch

SymbolSymbol / CompanyCompanyPricePrice Chg

AMTIApplied Molecular Transport Inc.

AMTIApplied Molecular Transport Inc.$0.26-3.13%

KRROKorro Bio, Inc.

KRROKorro Bio, Inc.$12.49-3.25%

CYCCCyclacel Pharmaceuticals, Inc.

CYCCCyclacel Pharmaceuticals, Inc.$6.37-5.98%

IMVIFIMV Inc.

IMVIFIMV Inc.$0.00+0.00%

HURATuHURA Biosciences, Inc.

HURATuHURA Biosciences, Inc.$2.13+0.95%

APGNApexigen, Inc.

APGNApexigen, Inc.$0.39+8.48%

Trending Stocks

SymbolSymbol / CompanyCompanyPricePrice Chg

PCGPG&E

PCGPG&E$13.27-0.20%

NVDANvidia

NVDANvidia$220.78+0.01%

TSLLDirexion Shares ETF Trust - Direxion Daily Tsla Bull 2x ETF

TSLLDirexion Shares ETF Trust - Direxion Daily Tsla Bull 2x ETF$9.97+0.11%

CNHCNH Industrial

CNHCNH Industrial$11.83+0.01%

NUNu Holdings

NUNu Holdings$14.55+0.02%

BITOProShares Trust - ProShares Bitcoin ETF

BITOProShares Trust - ProShares Bitcoin ETF$10.63+0.02%

AALAmerican Airlines Group

AALAmerican Airlines Group$13.43-0.02%

Questions About OBSV

What is the current price of ObsEva?

ObsEva is trading at N/A per share.

What is the 52-week range for ObsEva?

Over the past 52 weeks, ObsEva has traded between N/A and N/A.

How much debt does ObsEva have?

As of the most recent reporting period, ObsEva reported total debt of $3.03M.

How much cash does ObsEva have on hand?

ObsEva reported $14.96M in cash and cash equivalents in its most recent financial results.

What is ObsEva’s dividend yield?

ObsEva does not currently have a dividend yield.

ObsEva(OTC) OBSV

ObsEva Financials at a Glance

OBSV News

Motley Fool Moneyball Superscore

Our CEO Is Handing Members His Secret Weapon

About ObsEva

OBSV Financials

Key Financial Metrics (TTM)

Stock Overview

Financials (TTM)

ObsEva Performance Analysis

Revenue Growth Rate

Earnings Per Share Growth Rate

Quarterly Performance

Quarterly Fundamentals

Other Investments to Explore

People Also Watch

Trending Stocks

Questions About OBSV

What is the current price of ObsEva?

What is the 52-week range for ObsEva?

How much debt does ObsEva have?

How much cash does ObsEva have on hand?

What is ObsEva’s dividend yield?

Premium Investing Services